XM does not provide services to residents of the United States of America.
L
L

Lonza


News

Greencore, UCB, Unilever

EUROPE RESEARCH ROUNDUP-Greencore, UCB, Unilever July 26 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Greencore, UCB, and Unilever, on Friday. HIGHLIGHTS * Greencore GNC.L : HSBC raises target price to 190p from 160p * Lonza Group AG LONN.S : JP Morgan raises target price to CHF 645 from CHF 600 * Sartorius Stedim Biotech STDM.PA : HSBC cuts target price to EUR 310 from EUR 360 * UCB SA UCB.BR : TD Cowen raises target price to E
A
A
A
B
B
B
B
B
C
D
D
E
G
G
G
L
N
N
P
R
S
U
A
A
A
A
A
A
B
D
J

Swiss stocks - Factors to watch on July 26

Swiss stocks - Factors to watch on July 26 July 26 - Here are some of the main factors that may affect Swiss stocks on Friday: HOLCIM HOLN.S Reports Q2 results slightly ahead of forecasts. COMPANY STATEMENTS AMS OSRAM AMS.S Second quarter earnings release due. FORBO HOLDING FORN.S Confirms spring outlook for full year 2024. VONTOBEL VONN.S Half-year earnings release due.
A
L
N
S
J

European shares fall as earnings deluge disappoints

UPDATE 2-European shares fall as earnings deluge disappoints STOXX 600 down 0.7% Universal Music Group slumps as streaming growth disappoints Kering down after weak H2 forecast Besi tumbles as Q3 outlook disappoints Unilever gains after H1 profit beat Updated at 1600 GMT By Pranav Kashyap and Shashwat Chauhan July 25 (Reuters) - European shares closed lower on Thursday as a slate of downbeat earnings reports in several sectors including tech and luxury weighed, while a global run for safe haven
K
L
N
R
R
S
A
E
F
U
G

Swiss pharma firm Lonza hits 1-year high on earnings beat

BUZZ-Swiss pharma firm Lonza hits 1-year high on earnings beat Updates share move, adds milestone ** Shares in Lonza LONN.S jump 8% to their highest level in a year after the Swiss contract drug manufacturer's H1 core earnings fell less than expected by the market ** The stock tops the broad Swiss blue-chip index .SSMI , which was down 0.5% by 0717
L
S

Swiss pharma firm Lonza seen up on smaller-than-expected earnings drop

BUZZ-Swiss pharma firm Lonza seen up on smaller-than-expected earnings drop ** Shares in Swiss contract drug manufacturer Lonza LONN.S are seen rising 3.5% in the Julius Baer premarket indications after its H1 core earnings fell less than expected by the market ** H1 adjusted EBITDA fell to 893 million Swiss francs ($976.4 million), vs 802 million
L
J

Swiss pharma firm Lonza's profit falls less than feared, shares rise

UPDATE 3-Swiss pharma firm Lonza's profit falls less than feared, shares rise Rewrites with details on shares, adds analyst comment, details on Biologics unit, background; paragraphs 1-4 By Isabel Demetz and Andrey Sychev July 25 (Reuters) - Swiss contract drug manufacturer Lonza LONN.S reported a smaller-than-expected decline in first-half profit on Thursday, as a strong performance in its core Biologics unit partly offset weak demand for capsules.
C
L
S

Swiss pharma supplier Lonza reports lower half-year results

Swiss pharma supplier Lonza reports lower half-year results July 25 (Reuters) - Swiss contract drug manufacturer Lonza LONN.S reported a drop in its half year profit, hurt by lacklustre demand in its capsules and health ingredients businesses, but beat market estimates, it said on Thursday. It reported an adjusted core earnings before interest, taxes, depreciation and amortization (EBITDA) of 893 million Swiss francs ($976.4 million), compared to 922 million Swiss francs a year earlier.
L

Swiss stocks - Factors to watch on July 25

Swiss stocks - Factors to watch on July 25 ZURICH/GDANSK, July 25(Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: COMPANY STATEMENTS DORMAKABA DOKA.S Dormakaba expands production in India. LEONTEQ LEON.S Leonteq says outlook for 2024 is reaffirmed. BUCHER INDUSTRIES AG BUCN.S Bucher Industries says group expects lower sales in 2024. BACHEM HOLDING AG BANB.S Half-year results due.
L
N
R
S
J
S

Lonza Announces New Group Chief Executive Officer Wolfgang Wienand

BRIEF-Lonza Announces New Group Chief Executive Officer Wolfgang Wienand July 1 (Reuters) - LONZA GROUP AG LONN.S : WELCOMES NEW GROUP CHIEF EXECUTIVE OFFICER WOLFGANG WIENAND ALBERT M. BAEHNY WILL RETIRE FROM LONZA GROUP FOLLOWING A TRANSITION PERIOD WOLFGANG WIENAND COMMENCES HIS TENURE AS CHIEF EXECUTIVE OFFICER OF LONZA GROUP Source text for Ei
L

ABB, Klepierre, Ryanair

EUROPE RESEARCH ROUNDUP-ABB, Klepierre, Ryanair June 20 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including ABB, Klepierre and Ryanair, on Thursday. HIGHLIGHTS * ABB Ltd ABBN.S : Citigroup cuts to neutral from buy * ASM International NV ASMI.AS : Morgan Stanley raises to overweight from equal weight * Deutsche Lufthansa AG LHAG.DE : Stifel cuts to hold from buy * Klepierre LOIM.PA : HSBC raises to buy from hold * Ryanair RYA.I : UBS cu
A
A
B
C
D
D
G
K
K
L
L
L
M
N
N
P
S
W
A
A
A
L
R
S

AB Dynamics, Etteplan, Wise

EUROPE RESEARCH ROUNDUP-AB Dynamics, Etteplan, Wise June 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AB Dynamics, Etteplan and Wise, on Friday. HIGHLIGHTS * AB Dynamics Plc ABDP.L : Berenberg re-initiates coverage With Buy rating; PT 2,620p * Crest Nicholson CRST.L : Barclays cuts target price to 230p from 258p * Etteplan Oyj ETTE.HE : Evli Research raises to buy from hold * Halma HLMA.L : Barclays raises target price to 284
B
C
E
H
H
J
L
O
O
P
R
S
S
T
U
V
V
Z
H
A
R

Asmi, Beiersdorf, SSE

EUROPE RESEARCH ROUNDUP-Asmi, Beiersdorf, SSE June 7 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Asmi, Beiersdorf and SSE, on Friday. HIGHLIGHTS * Arcadis NV ARDS.AS : KBC Securities raises to accumulate from buy * Asmi ASMI.AS : Berenberg raises target price to EUR 720 from EUR 640 * Beiersdorf BEIG.DE : HSBC raises target price to EUR 158 from EUR 152 * Nibe Industrier AB NIBEB.ST : HSBC cuts to hold from buy * SSE SSE.L : HS
A
B
B
C
D
E
E
I
J
L
L
S
W

Asmi, Beiersdorf, SSE

CORRECTED-EUROPE RESEARCH ROUNDUP-Asmi, Beiersdorf, SSE Corrects Greenyard NV entry to say KBC Securities raises target price to EUR 9.5 from EUR 8.5 (not 6.30) and Arcadis NV entry to say KBC Securities cuts (not raises) to 'accumulate' from 'buy'; raises target price to EUR 66 from EUR 61 (not 61.7 June 7 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Asmi, Beiersdorf and SSE, on Friday.
A
B
B
B
C
D
D
E
E
I
J
K
L
L
P
R
S
V
V
V
W
P
S



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.